Residency · Residency · Internal Medicine

Sickle Cell Disease: Acute Vaso-Occlusive Crisis and Complications

Overview

Sickle cell disease (SCD) is an autosomal recessive hemoglobinopathy caused by a point mutation in the beta-globin gene (glutamate to valine at position 6). Under deoxygenated conditions, hemoglobin S polymerizes, causing red blood cells to sickle. This leads to vaso-occlusion, hemolysis, and chronic organ damage. SCD is a multisystem disease with both acute crises and chronic complications. Disease-modifying therapies including hydroxyurea, L-glutamine, and gene therapy have improved outcomes but remain underutilized.

Acute Vaso-Occlusive Crisis (VOC)

Pathophysiology

Vaso-occlusive crises are triggered by HbS polymerization, which produces rigid sickled red blood cells that occlude the microvasculature, causing tissue ischemia and infarction. Common triggers include dehydration, infection, cold exposure, stress, hypoxia, altitude, and menstruation.

Pain Management

Acute pain crisis is a medical emergency, and undertreated pain is common, contributing to healthcare distrust among patients with SCD. Aggressive, individualized analgesia is required. IV opioids should be administered within 30 minutes of presentation per ACS guidelines, using morphine or hydromorphone at patient-specific doses while avoiding meperidine due to seizure risk. Pain should be reassessed and medications redosed every 15 to 30 minutes until control is achieved. Once initial control is established, scheduled dosing is preferred over PRN administration. Patient-controlled analgesia (PCA) is appropriate for severe crises.

Adjunctive therapies include NSAIDs (ketorolac 15-30 mg IV, avoiding use in renal impairment), acetaminophen, lidocaine patches for localized pain, and warm compresses (never cold, which can worsen sickling). IV fluids should be isotonic at maintenance rate, avoiding overhydration which risks precipitating acute chest syndrome. Incentive spirometry every 2 hours while awake is critical for preventing acute chest syndrome. Clinicians must not under-dose opioids based on bias — patients with SCD have genuine, severe pain and often require higher doses due to chronic opioid exposure.

<image>Acute vaso-occlusive crisis management algorithm showing rapid opioid administration, adjunctive therapies, incentive spirometry, and monitoring for complications including acute chest syndrome</image>

Acute Chest Syndrome (ACS)

Definition

Acute chest syndrome is defined as a new pulmonary infiltrate on chest X-ray plus at least one of the following: fever, chest pain, respiratory symptoms, or hypoxia. It is the leading cause of death in adults with SCD.

Pathophysiology

The pathophysiology is multifactorial, involving in situ pulmonary vascular occlusion, fat embolism from bone marrow necrosis, infection (Chlamydia, Mycoplasma, S. pneumoniae), and hypoventilation from chest wall pain.

Management

Management includes broad-spectrum antibiotics covering community-acquired pneumonia pathogens plus atypicals (ceftriaxone plus azithromycin), supplemental oxygen targeting SpO2 above 95%, and transfusion. Simple transfusion is appropriate if hemoglobin is below 9-10 g/dL and the patient is not severely ill. Exchange transfusion is indicated for severe ACS (PaO2 below 60, progressive infiltrates, multiorgan failure, or rapid clinical deterioration), with a target HbS below 30%. Incentive spirometry every 2 hours, adequate pain control to prevent splinting and atelectasis, and bronchodilators if wheezing are all part of the management. ICU admission should be considered for severe cases, with intubation for refractory hypoxemia.

Exchange Transfusion

Indications

Exchange transfusion is indicated for severe acute chest syndrome, acute stroke, multiorgan failure, pre-operative preparation for high-risk surgery, and refractory priapism.

Goals

The goals are to reduce HbS to below 30% while maintaining hemoglobin at 10 g/dL (avoiding hemoglobin above 10-11 in SCD due to increased viscosity). Either manual exchange (phlebotomy plus transfusion) or automated erythrocytapheresis (preferred if available) can be used.

Transfusion Considerations

Extended phenotype matching (C, E, and Kell at minimum) is essential to reduce alloimmunization risk. SCD patients have high alloimmunization rates (20-50%) due to antigen mismatch between the predominantly African-descent patient population and the blood supply. Hemoglobin S-negative, sickle-negative units are required.

Other Acute Complications

Stroke

In children, ischemic stroke predominates, and transcranial Doppler screening identifies high-risk patients. In adults, both ischemic and hemorrhagic strokes occur, with emergent exchange transfusion indicated for acute events. A chronic transfusion program is used for secondary prevention.

Splenic Sequestration

This involves rapid splenic enlargement with trapping of red blood cells, causing acute anemia and hypovolemia. It is more common in children, though adults with HbSC or HbS-beta+ thalassemia may retain splenic tissue. Management includes aggressive IV fluids and RBC transfusion, with caution since rapid transfusion can cause hyperviscosity as sequestered cells are released.

Aplastic Crisis

Parvovirus B19 infection causes temporary cessation of erythropoiesis, resulting in severe anemia with absent reticulocytes (reticulocyte count near zero). The condition is self-limited over 1 to 2 weeks, with transfusion for symptomatic anemia. Respiratory isolation is necessary as patients are contagious.

Priapism

Sustained, painful erection results from vaso-occlusion in the corpora cavernosa. Duration exceeding 4 hours constitutes a urologic emergency. Initial management includes hydration, analgesia, and pseudoephedrine. Urologic consultation provides aspiration and irrigation of the corpora with phenylephrine injection. Exchange transfusion is reserved for refractory cases.

<image>Major acute complications of sickle cell disease showing acute chest syndrome, stroke, splenic sequestration, aplastic crisis, and priapism with key diagnostic features and immediate management steps</image>

Disease-Modifying Therapies

Hydroxyurea

Hydroxyurea is the cornerstone of SCD management and is FDA-approved for adults and children. Its mechanism involves increasing HbF production (which inhibits HbS polymerization), reducing WBC and platelet counts (anti-inflammatory effect), and increasing nitric oxide availability. Benefits include reducing VOC frequency by approximately 50%, reducing ACS, reducing transfusion need, and improving survival. Dosing starts at 15 mg/kg/day and is titrated to maximum tolerated dose with a goal of mild myelosuppression while maintaining ANC above 2000. Monitoring requires CBC every 4 to 8 weeks during titration along with renal and hepatic function. Despite its proven benefits, hydroxyurea remains underutilized due to provider unfamiliarity, patient concerns about side effects (teratogenicity requiring contraception), and adherence challenges.

L-Glutamine (Endari)

L-glutamine reduces oxidative stress in sickled RBCs and is FDA-approved for reducing VOC frequency in patients 5 years and older. It provides modest benefit and can be added to hydroxyurea.

Voxelotor (Oxbryta)

Voxelotor is an HbS polymerization inhibitor that increases oxygen affinity of hemoglobin. It is FDA-approved for SCD and improves hemoglobin levels while reducing hemolysis markers. However, it may not reduce VOC frequency, and post-marketing data have been mixed. Voluntary market withdrawal has occurred in some regions pending additional data.

Crizanlizumab (Adakveo)

Crizanlizumab is an anti-P-selectin monoclonal antibody that reduces cell adhesion to the endothelium. It was initially FDA-approved based on the SUSTAIN trial showing reduced VOC. However, the phase 3 STAND trial failed to show significant VOC reduction, leading to market withdrawal. This highlights the challenge of translating phase 2 results in SCD.

Gene Therapy

Exagamglogene autotemcel (exa-cel, brand name Casgevy) uses CRISPR-Cas9 gene editing to modify the BCL11A gene, reactivating fetal hemoglobin production. It is FDA-approved and potentially curative, with early data showing near-elimination of VOC, though it requires myeloablative conditioning with significant toxicity risk. Lovotibeglogene autotemcel (lovo-cel, brand name Lyfgenia) uses a lentiviral vector to produce modified anti-sickling hemoglobin (HbAT87Q). It is also FDA-approved but carries concerns about a rare hematologic malignancy signal. Barriers to gene therapy include cost (over $2 million), access limitations, need for specialized centers, and pending long-term safety data.

<image>Disease-modifying therapies for sickle cell disease showing hydroxyurea as foundation, add-on options (L-glutamine, voxelotor), and emerging gene therapies (exa-cel, lovo-cel) with mechanisms of action</image>

Chronic Complications

Chronic pain is often undertreated and requires a multidisciplinary approach. Avascular necrosis primarily affects the hips and shoulders and may require arthroplasty. Chronic kidney disease results from sickle nephropathy progressing from hyperfiltration to proteinuria to CKD, with ACEi/ARB for proteinuria. Pulmonary hypertension is screened with echocardiography, and an elevated tricuspid regurgitant velocity of 2.5 m/s or greater warrants further evaluation. Annual dilated eye exams screen for proliferative retinopathy, which is especially common in HbSC disease. Iron overload from chronic transfusions requires chelation with deferasirox or deferoxamine. Leg ulcers are common and difficult to heal, requiring dedicated wound care and compression.

Clinical Pearls

Incentive spirometry every 2 hours while awake is one of the most important interventions to prevent ACS during VOC hospitalization. Hemoglobin should never be transfused above 10 g/dL in SCD because increased viscosity from high hemoglobin worsens vaso-occlusion. Acute chest syndrome can develop during a VOC admission, so close monitoring for new cough, fever, chest pain, or hypoxia is essential. Parvovirus B19-induced aplastic crisis is characterized by severe anemia with reticulocyte count near zero, distinguishing it from other causes of acute anemia in SCD. Hydroxyurea is dramatically underutilized — every SCD patient with recurrent VOC should be offered it, and the BABY HUG trial showed benefit even in young children. IV fluid overhydration during VOC can precipitate or worsen ACS, so maintenance rate rather than aggressive resuscitation should be used.

References

• Yawn BP, et al. Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members. JAMA. 2014;312:1033-1048.
• Charache S, et al. Effect of Hydroxyurea on the Frequency of Painful Crises in SCD (MSH Trial). N Engl J Med. 1995;332:1317-1322.
• Frangoul H, et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Transfusion-Dependent Thalassemia. N Engl J Med. 2021;384:252-260.
• Howard J, et al. Guidelines on the Management of Acute Chest Syndrome in SCD. Br J Haematol. 2015;169:492-505.
• Ataga KI, et al. Crizanlizumab for the Prevention of Pain Crises in SCD (SUSTAIN). N Engl J Med. 2017;376:429-439.

Read this lecture as Markdown